Goal: Develop an in vivo strategy to verify Ames data within the framework of ICH M7.
Phase I:
Assessed in vitro/in vivo concordance for exemplar nitrosamines and NDSRIs
Project Leads: Alejandra Trejo-Martin (Gilead), Bob Jolly (Eli Lilly)
Anonymous data provided from drug manufacturers covering 33 nitrosamines
Conducted dose-response testing of in vivo mutagenicity for 7 exemplar nitrosamines
Outcomes:
- Determined effectiveness of in vitro tests to predict in vivo outcomes
- Generated in vivo BMDL values for comparison with carcinogenic BMDL10 values
- Publication: Pending internal review before journal submission
Completed literature review and analysis on less-than-lifetime (LTL) exposure relevance
Project Lead: Susan Felter (P&G)
Literature search to determine the applicability of LTL to NAs in general
Eight nitrosamines met inclusion criteria for the review
Outcomes:
- Found stronger correlation between tumor incidence and Lifetime Cumulative Dose (LCD) versus dose rate or exposure duration
- Supported using LCD as the preferred dose metric for cancer risk assessment
- Publication: Approved with minor revisions (May 2025), Regulatory Toxicology & Pharmacology
Phase II:
Advancing testing of additional N-nitroso compounds, including ureas and carbamates
Project Leads: Wen Sun (Pfizer) and TBD
Goals:
- Evaluate correlation between carcinogenicity data and in vivo Pig-a assay results
- Develop a process for setting acceptable intakes (AIs)
- Expand testing to include Comet assay and ecNGS as resources permit
Carcinogenicity Potency Analysis
Goal:
- Analyze relationship between mutagenic potency (TGR data) and carcinogenic potency
- Work to proceed under the HESI GTTC Quantitative Analysis Workgroup
Less-than-lifetime (LTL) exposure literature follow-up
Project Lead: Susan Felter (P&G)
Goals:
- Evaluate relevance of single, intermittent, and LTL exposures in nitrosamine risk assessment
- Refine ICH M7 adjustment factors as needed
Initiating LTL mutagenicity study design and experimental work
Project Leads: Zhanna Sobel (Merck & Co., Inc.), Bob Jolly (Eli Lilly)
Goal: Prospectively evaluate the effect of exposure duration on mutagenic outcomes
Working Group Leadership:
Joel Bercu (Gilead)
Robert Jolly (Eli Lilly)
Sheroy Minocherhomji (Eli Lilly)
Timothy McGovern (White Oak Regulatory Tox, LLC)